{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T09:08:32Z","timestamp":1793610512937,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","award":["CGRPVVQ0011"],"award-info":[{"award-number":["CGRPVVQ0011"]}],"id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.diabres.2026.113115","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T07:42:26Z","timestamp":1769499746000},"page":"113115","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Comparative risk of infections with GLP-1 receptor agonists versus SGLT2 inhibitors in patients with advanced chronic kidney disease and type 2 diabetes"],"prefix":"10.1016","volume":"233","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3782-8189","authenticated-orcid":false,"given":"Ching Chung","family":"Hsiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Jin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Chun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chieh-Li","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8461-6456","authenticated-orcid":false,"given":"Wen-Yu","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1302-1885","authenticated-orcid":false,"given":"Yu-Wei","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mon-Ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7814-4723","authenticated-orcid":false,"given":"Jeng How","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3561-4689","authenticated-orcid":false,"given":"Ming-Hsien","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.diabres.2026.113115_b0005","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nrneph.2015.173","article-title":"Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease","volume":"12","author":"Thomas","year":"2016","journal-title":"Nat Rev Nephrol"},{"issue":"7","key":"10.1016\/j.diabres.2026.113115_b0010","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1007\/s00125-024-06102-x","article-title":"Diabetes and infection: review of the epidemiology, mechanisms and principles of treatment","volume":"67","author":"Holt","year":"2024","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.diabres.2026.113115_b0015","doi-asserted-by":"crossref","DOI":"10.3390\/toxins12050300","article-title":"Chronic kidney disease-associated immune dysfunctions: impact of protein-bound uremic retention solutes on immune cells","volume":"12","author":"Espi","year":"2020","journal-title":"Toxins (Basel)"},{"issue":"22","key":"10.1016\/j.diabres.2026.113115_b0020","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.2174\/1381612826666200213123029","article-title":"inflammatory related cardiovascular diseases: from molecular mechanisms to therapeutic targets","volume":"26","author":"Sardu","year":"2020","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.diabres.2026.113115_b0025","article-title":"Sodium-glucose cotransporter 2 inhibitors mechanisms of action: a review","volume":"8","author":"Fonseca-Correa","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"11","key":"10.1016\/j.diabres.2026.113115_b0030","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1111\/dom.13420","article-title":"Effects of liraglutide on gallbladder emptying: a randomized, placebo-controlled trial in adults with overweight or obesity","volume":"20","author":"Nexoe-Larsen","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1016\/j.diabres.2026.113115_b0035","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1080\/00365521.2018.1530297","article-title":"Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs","volume":"53","author":"Rehfeld","year":"2018","journal-title":"Scand J Gastroenterol"},{"issue":"5","key":"10.1016\/j.diabres.2026.113115_b0040","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","article-title":"Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials","volume":"182","author":"He","year":"2022","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.diabres.2026.113115_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2025.112324","article-title":"GLP-1 receptor agonists and hospitalization due to infections in patients with type 2 diabetes: a nationwide cohort study","volume":"226","author":"Wang","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"10.1016\/j.diabres.2026.113115_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2025.106645","article-title":"Association of glucagon-like peptide-1 receptor agonist use with risk of infections: a systematic review and meta-analysis","volume":"91","author":"Han","year":"2025","journal-title":"J Infect"},{"issue":"9","key":"10.1016\/j.diabres.2026.113115_b0055","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.34485","article-title":"SGLT2 inhibitors and external genital infection in male patients with type 2 diabetes","volume":"8","author":"Cheng","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.diabres.2026.113115_b0060","doi-asserted-by":"crossref","DOI":"10.1155\/jdr\/5888495","article-title":"SGLT2 inhibitors and the risk of infections in type 2 diabetes: systematic review and meta-analyses of real-world evidence","volume":"2025","author":"Alfonso Arvez","year":"2025","journal-title":"J Diabetes Res"},{"issue":"5","key":"10.1016\/j.diabres.2026.113115_b0065","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00592-018-1116-0","article-title":"SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials","volume":"55","author":"Puckrin","year":"2018","journal-title":"Acta Diabetol"},{"issue":"4","key":"10.1016\/j.diabres.2026.113115_b0070","doi-asserted-by":"crossref","first-page":"248","DOI":"10.7326\/M18-3136","article-title":"Sodium-glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: a population-based cohort study","volume":"171","author":"Dave","year":"2019","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.diabres.2026.113115_b0075","doi-asserted-by":"crossref","first-page":"592","DOI":"10.2215\/CJN.0000000000000115","article-title":"Safety of sodium-glucose cotransporter-2 inhibitors in patients with CKD and type 2 diabetes: population-based US cohort study","volume":"18","author":"Fu","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.diabres.2026.113115_b0080","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1210\/clinem\/dgab274","article-title":"Clinical adverse events associated with sodium-glucose cotransporter 2 inhibitors: a meta-analysis involving 10 randomized clinical trials and 71 553 individuals","volume":"106","author":"Lin","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"10.1016\/j.diabres.2026.113115_b0085","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.amjcard.2019.10.029","article-title":"Safety of sodium-glucose co-transporter 2 inhibitors","volume":"124","author":"McGill","year":"2019","journal-title":"Am J Cardiol"},{"issue":"12","key":"10.1016\/j.diabres.2026.113115_b0090","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s40264-020-01010-6","article-title":"Potential safety issues with use of sodium-glucose cotransporter 2 inhibitors, particularly in people with type 2 diabetes and chronic kidney disease","volume":"43","author":"Milder","year":"2020","journal-title":"Drug Saf"},{"issue":"2","key":"10.1016\/j.diabres.2026.113115_b0095","doi-asserted-by":"crossref","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"key":"10.1016\/j.diabres.2026.113115_b0100","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1516126","article-title":"A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX","volume":"16","author":"Ludwig","year":"2025","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.diabres.2026.113115_b0105","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.50050","article-title":"Sodium-glucose cotransport protein 2 inhibitors in patients with type 2 diabetes and acute kidney disease","volume":"7","author":"Pan","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.diabres.2026.113115_b0110","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/jdi.14361","article-title":"Enhanced renoprotective effects of combined glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: Real-world evidence","volume":"16","author":"Jhu","year":"2025","journal-title":"J Diabetes Investig"},{"issue":"1","key":"10.1016\/j.diabres.2026.113115_b0115","doi-asserted-by":"crossref","DOI":"10.21037\/atm.2018.12.10","article-title":"Balance diagnostics after propensity score matching","volume":"7","author":"Zhang","year":"2019","journal-title":"Ann Transl Med"},{"issue":"6","key":"10.1016\/j.diabres.2026.113115_b0120","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1053\/j.ajkd.2016.09.018","article-title":"CKD and risk for hospitalization with infection: the Atherosclerosis Risk in Communities (ARIC) study","volume":"69","author":"Ishigami","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.diabres.2026.113115_b0125","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1053\/j.ackd.2019.01.004","article-title":"Immune dysfunction and risk of infection in chronic kidney disease","volume":"26","author":"Syed-Ahmed","year":"2019","journal-title":"Adv Chronic Kidney Dis"},{"issue":"1","key":"10.1016\/j.diabres.2026.113115_b0130","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqae155","article-title":"Physiology and pharmacology of effects of GLP-1-based therapies on gastric, biliary and intestinal motility","volume":"166","author":"Jalleh","year":"2024","journal-title":"Endocrinology"},{"issue":"9","key":"10.1016\/j.diabres.2026.113115_b0135","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1111\/dom.12926","article-title":"Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): data from randomized controlled trials","volume":"19","author":"Monami","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2026.113115_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108087","article-title":"Cholelithiasis in patients treated with glucagon-like peptide-1 receptor: an updated meta-analysis of randomized controlled trials","volume":"161","author":"Nreu","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"10.1016\/j.diabres.2026.113115_b0145","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00592-022-01989-7","article-title":"Effects of sodium-glucose co-transporter-2 inhibitors on kidney, cardiovascular, and safety outcomes in patients with advanced chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials","volume":"60","author":"Cao","year":"2023","journal-title":"Acta Diabetol"},{"issue":"1","key":"10.1016\/j.diabres.2026.113115_b0150","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1038\/s41598-025-86172-y","article-title":"Real-world effectiveness and safety of sodium-glucose co-transporter 2 inhibitors in chronic kidney disease","volume":"15","author":"Hunsuwan","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.diabres.2026.113115_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101337","article-title":"Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: effects of sodium-glucose co-transporter2 inhibitor treatment","volume":"54","author":"D'Onofrio","year":"2021","journal-title":"Mol Metab"},{"issue":"16","key":"10.1016\/j.diabres.2026.113115_b0160","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1111\/bph.15850","article-title":"Amelioration of endothelial dysfunction by sodium glucose co-transporter 2 inhibitors: pieces of the puzzle explaining their cardiovascular protection","volume":"179","author":"Li","year":"2022","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.diabres.2026.113115_b0165","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes, C.K.D.W.G., KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024; 105(4S): S117\u2013S314.","DOI":"10.1016\/j.kint.2023.10.018"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726000343?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726000343?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T08:41:28Z","timestamp":1779093688000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822726000343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":33,"alternative-id":["S0168822726000343"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113115","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative risk of infections with GLP-1 receptor agonists versus SGLT2 inhibitors in patients with advanced chronic kidney disease and type 2 diabetes","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113115","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113115"}}